EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study

Shuai Liang, Hanyu Wang, Yingyun Zhang, Haixia Tian, Chengming Li, Dong Hua iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.7208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Shuai Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Wuxi, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Chemoradiotherapy, ErbB Receptors, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cohort and Clinical Research Program of Wuxi Medical Center, Nanjing Medical University, Medical Innovation Team of Wuxi, Top Medical Expert Team of 2021 Taihu Talent Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To elucidate the potential benefits of combining radiotherapy and epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) for individuals with Stage IV lung adenocarcinoma (LUAD) harboring either exon 19 deletion ( 19‐Del ) or exon 21 L858R mutation ( 21‐L858R ).

Methods

In this real‐world retrospective study, 177 individuals with Stage IV LUAD who underwent EGFR‐TKIs and radiotherapy at Shandong Cancer Hospital from June 2012 to August 2017 were included. The main focus of this real‐world study was overall survival (OS).

Results

The clinical characteristics of patients with Stage IV LUAD harboring 19‐Del were similar to those harboring 21‐L858R ( p > 0.05). Overall, the patients had a median OS (mOS) of 32.0 months (95% confidence interval [CI]: 28.6–35.5). Subsequently, multivariate analysis indicated that both EGFR mutations and thoracic radiotherapy were independent predictors of OS ( p = 0.001 and 0.013). Furthermore, subgroup analysis highlighted a longer OS for the 19‐Del group compared to the 21‐L858R group, especially when EGFR‐TKIs were combined with bone metastasis or thoracic radiotherapy (mOS: 34.7 vs. 25.1 months and 51.0 vs. 29.6 months; p = 0.0056 and 0.0013, respectively). However, no significant differences were found in OS when considering patients who underwent brain metastasis radiotherapy (mOS: 34.7 vs. 25.1 months; p = 0.088).

Conclusions

Patients with Stage IV LUAD harboring 19‐Del experience a notably prolonged OS following combined therapy with EGFR‐TKIs and radiotherapy, while this OS benefit is observed despite the absence of substantial differences in the clinical characteristics between the 19‐Del and 21‐L858R groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungChemoradiotherapyErbB ReceptorsLung NeoplasmsMutationTyrosine Kinase InhibitorsAdultAgedFemaleHumansMaleMiddle AgedExonsNeoplasm StagingPrognosisProtein Kinase InhibitorsRetrospective StudiesSequence Deletion

Stichwörter der Autor:innen

Stage IV lung adenocarcinomaepidermal growth factor receptor‐tyrosine kinase inhibitorexon 19 deletionexon 21 L858R mutationradiotherapy

Substanzen

EGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Wuxi, China.
  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • The Affiliated Children's Hospital of Jiangnan University, Wuxi School of Medicine, Wuxi, China.
  • Department of oncology, Shengli Oilfield Central Hospital, Dongying, China.

ORCID-Profile: Dong Hua

Förderung

  • Cohort and Clinical Research Program of Wuxi Medical Center, Nanjing Medical University
  • Medical Innovation Team of Wuxi
  • Top Medical Expert Team of 2021 Taihu Talent Plan Project
  • Major Program of Wuxi Medical Center, Nanjing Medical University

Zitieren

APA

Liang, S., Wang, H., Zhang, Y., Tian, H., Li, C., & Hua, D. (2024). Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study. Cancer Medicine. https://doi.org/10.1002/cam4.7208

Vancouver

Liang S, Wang H, Zhang Y, Tian H, Li C, Hua D. Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study. Cancer Medicine. 2024. doi:10.1002/cam4.7208

BibTeX
@article{Liang2024,
  author = {Liang, Shuai and Wang, Hanyu and Zhang, Yingyun and Tian, Haixia and Li, Chengming and Hua, Dong},
  title = {Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7208}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche